Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/8b/8b/7f/8b8b7fde-2720-71bb-ca07-74c8551e9002/mza_12883600428468111473.jpg/600x600bb.jpg
Haemline
Haemline Team
14 episodes
3 months ago
In double cord blood transplantation, one unit engrafts and the other is rejected—but the losing unit might be doing more than previously imagined. A 2025 Blood Advances study from the Eurocord–EBMT registry reveals how the immunological battle between cord units can be redirected against leukaemia, particularly when the patient and losing unit share the right HLA mismatches. In this episode, we unpack the elegant biology behind this unintended vaccine effect, explore the surprising lack of e...
Show more...
Education
RSS
All content for Haemline is the property of Haemline Team and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In double cord blood transplantation, one unit engrafts and the other is rejected—but the losing unit might be doing more than previously imagined. A 2025 Blood Advances study from the Eurocord–EBMT registry reveals how the immunological battle between cord units can be redirected against leukaemia, particularly when the patient and losing unit share the right HLA mismatches. In this episode, we unpack the elegant biology behind this unintended vaccine effect, explore the surprising lack of e...
Show more...
Education
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/8b/8b/7f/8b8b7fde-2720-71bb-ca07-74c8551e9002/mza_12883600428468111473.jpg/600x600bb.jpg
First-Line Ven/Aza/Revumenib for AML?
Haemline
12 minutes
3 months ago
First-Line Ven/Aza/Revumenib for AML?
Could targeting the menin–KMT2A axis up front improve outcomes in older adults with NPM1-mutated or KMT2A-rearranged AML? In this episode, we examine new phase I data from Zeidner and colleagues, published in The Journal of Clinical Oncology in June 2025, investigating revumenib in combination with azacitidine and venetoclax for newly diagnosed patients ineligible for intensive therapy. We explore the shared biological mechanism linking these two subtypes, the rationale for adding menin inhib...
Haemline
In double cord blood transplantation, one unit engrafts and the other is rejected—but the losing unit might be doing more than previously imagined. A 2025 Blood Advances study from the Eurocord–EBMT registry reveals how the immunological battle between cord units can be redirected against leukaemia, particularly when the patient and losing unit share the right HLA mismatches. In this episode, we unpack the elegant biology behind this unintended vaccine effect, explore the surprising lack of e...